Back to search results

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Leiomyosarcoma · Sarcoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Gabriel Tinoco, MD) · Gabriel.Tinoco@osumc.edu
    Contact: Principal Investigator (Gabriel Tinoco, MD)
Study leads

  • Gabriel Tinoco, MD

    Principal Investigator

    Ohio State University Comprehensive Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)